Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

DSpace Repository

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

Author: Baertsch, Marc-Andrea; Schlenzka, Jana; Mai, Elias K.; Merz, Maximilian; Hillengass, Jens; Raab, Marc S.; Hose, Dirk; Wuchter, Patrick; Ho, Anthony D.; Jauch, Anna; Hielscher, Thomas; Kunz, Christina; Luntz, Steffen; Klein, Stefan; Schmidt-Wolf, Ingo G. H.; Goerner, Martin; Schmidt-Hieber, Martin; Reimer, Peter; Graeven, Ullrich; Fenk, Roland; Salwender, Hans; Scheid, Christof; Nogai, Axel; Haenel, Mathias; Lindemann, Hans W.; Martin, Hans; Noppeney, Richard; Weisel, Katja; Goldschmidt, Hartmut
Tübinger Autor(en):
Weisel, Katja
Published in: Bmc Cancer (2016), Bd. 16, Article 290
Verlagsangabe: Biomed Central Ltd
Language: English
Full text: http://dx.doi.org/10.1186/s12885-016-2321-2
ISSN: 1471-2407
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)